04:46:36 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


Inhalation Sciences Sweden, ISAB, är ett forskningsbolag. Idag innehas störst fokus mot framställning och utvecklande av laboratorieinstrument. Instrumenten används för att mäta partiklar i inandningsluften och hur luftens sammansättning påverkar lungorna. Bolaget säljer produkter under varierade varumärken, främst på den europeiska marknaden. Inhalation Sciences Sweden grundades 2004 och har sitt huvudkontor i Huddinge.


2022-11-22 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-06-08 Ordinarie utdelning ISAB 0.00 SEK
2022-05-23 Kvartalsrapport 2022-Q1
2022-05-06 Årsstämma 2022
2022-02-28 Bokslutskommuniké 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-06-22 Extra Bolagsstämma 2021
2021-06-09 Ordinarie utdelning ISAB 0.00 SEK
2021-06-08 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-06-12 Extra Bolagsstämma 2020
2020-05-13 Ordinarie utdelning ISAB 0.00 SEK
2020-05-12 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-22 Årsstämma 2019
2019-05-16 Kvartalsrapport 2019-Q1
2019-05-10 Ordinarie utdelning ISAB 0.00 SEK
2019-02-21 Bokslutskommuniké 2018
2018-12-13 Extra Bolagsstämma 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-24 Ordinarie utdelning ISAB 0.00 SEK
2018-05-23 Årsstämma 2018
2018-05-16 Kvartalsrapport 2018-Q1
2018-02-22 Bokslutskommuniké 2017
2017-11-17 Kvartalsrapport 2017-Q3
2017-08-28 Kvartalsrapport 2017-Q2
2021-12-08 10:34:40

(Stockholm, 8 December 2021) Inhalation Research Services (IRS), the contract research organization of Inhalation Sciences Sweden AB (ISAB), has received an order worth 55 752 Euros for a new research project from Italian pharma company Chiesi. The joint research project is between Chiesi and the Institute of Environmental Medicine (IMM) at Karolinska Institutet (KI). Both Chiesi and IMM, leading research bodies within inhalation, are returning ISAB customers.

The IRS study is valued at 55 752 Euros. It will be carried out at IMM's research facilities at Karolinska Insittutet in Stockholm under the leadership of KI's Professor Lena Palmberg, a long-term ISAB collaborator.

The study will use XposeALI[®], ISAB's highly innovative in vitro cell culturing tool that combines the aerosol capability from PreciseInhale[®] with cell exposures at an Air Liquid Interface that mimic closely the physiologic processes as they happen in the lungs.

2021 has seen significant events around XposeALI[®]: in October it was chosen to test a Mars dust surrogate for the European Space Agency in another IMM research project. In the same month its US patent was extended. In November the module received its US Registered Trademark, together with ISAB's core aerosol generating system PreciseInhale[®] and in vitro dissolution module DissolvIt[®].

CEO Manoush Masarrat: "Both Chiesi and KI are recognized worldwide as leading bodies in inhalation research. It is a powerful endorsement of our technology that they choose us time and again to achieve their early stage results. We are delighted too to see them recognize the unique capabilities and benefits of XposeALI[®]. We believe it will become a recognized leader within its niche."